KIT and melanoma: Fedorenko and his colleague presented a preclinical study for NRAS‐mutant melanoma with amuvatinib, which is a multikinase inhibitor targeting mutant Kit, c‐MET, PDGFR‐α, and Rad51 [351, 352].